Early Phase 1 Ovarian Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People newly diagnosed with stage I–IV colorectal or ovarian cancer, grade 1 or 2 endometrial cancer, brain tumors, or sarcoma.
- People who have surgery planned for at least 2 weeks after the day they enroll in the study.
- People who are able to understand and willing to sign a written consent form for this study and a related tissue bank study at the University of South Florida and Tampa General Hospital.
- People aged 18 or older.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who are unable to give informed consent due to a mental condition that prevents them from understanding what the study involves.
- People who the study investigator believes are unlikely to follow the study plan as required.
- People with an allergy to fish, seafood, aspirin, anti-inflammatory pain medicines (such as ibuprofen or naproxen), a medicine called montelukast, or nuts.
- People with a history of asthma or a lung condition called chronic obstructive pulmonary disease (COPD).
- People with a history of a condition called phenylketonuria (PKU), which affects how the body processes certain proteins.
- People with a history of a psychiatric illness, such as major depression, anxiety disorder, bipolar disorder, or obsessive-compulsive disorder, among others.
- People whose surgery is scheduled more than 8 weeks after the day they enroll in the study.
- People where no clear tumour or mass has been found on a camera examination of the bowel (endoscopy) or on medical imaging.
- People who have more than one type of cancer at the same time.
- People with high blood pressure or diabetes that is not well controlled.
- People with chronic liver disease or liver scarring (cirrhosis).
- People with reduced liver function or persistently raised levels of certain liver-related markers in blood tests (confirmed by a repeat test).
- People with bleeding conditions, such as problems with how their blood clots, including haemophilia, von Willebrand disease, or similar disorders.
- People currently taking blood-thinning or anti-clotting medicines, such as aspirin, clopidogrel, warfarin, or heparin, among others.
- People with a significant or severe infection that has not cleared up, whether recent or ongoing.
- People with significantly reduced bone marrow function, or notably low levels of red blood cells, white blood cells, or platelets on blood tests (confirmed by a repeat test), based on specific thresholds (confirm with trial site).
- People who regularly take medicines that suppress the immune system.
- People who have had an organ transplant.
- People who need emergency surgery.
- People who are pregnant, breastfeeding, or planning to become pregnant during the study.
- Women of childbearing potential who are not using an effective form of contraception and/or are unwilling or unable to be tested for pregnancy.
- People who are currently in prison.
- People who have taken leukotriene inhibitor medicines, omega-3 supplements, or eaten almonds in the past 4 weeks.
- People who have taken part in another clinical drug trial in the past 6 months.
- People who, after being enrolled and assigned a specific study treatment, consume products that belong to a different group in the study (for example, a participant assigned to take a specific supplement who also starts eating daily almonds, which belong to another study group).
- People who are unable to swallow oral medicines or chew almonds.
- People who have already started pre-surgery cancer treatment (called neoadjuvant therapy) for their cancer diagnosis.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jorge Marcet, University of South Florida
Phone: 813-505-4787
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Where this trial is recruiting
Primary endpoints
Quantity of lipid mediators in a tumor specimen after 2 weeks of study treatment.; Quantity of lipid mediators in a non-cancerous (i.e. normal) tissue from the resected surgical specimen after 2 weeks of study treatment.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.